Saturday, June 10, 2017

Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474

Science  09 Jun 2017: Vol. 356, Issue 6342  1084-1087
  • Annelot C. M. van Esbroeck1,*
  • Antonius P. A. Janssen1,*
  • Armand B. Cognetta III2,*
  • Daisuke Ogasawara2,*
  • Guy Shpak3
  • Mark van der Kroeg3
  • Vasudev Kantae4
  • Marc P. Baggelaar1
  • Femke M. S. de Vrij3
  • Hui Deng1
  • Marco Allarà5
  • Filomena Fezza6
  • Zhanmin Lin7
  • Tom van der Wel1
  • Marjolein Soethoudt1
  • Elliot D. Mock1
  • Hans den Dulk1
  • Ilse L. Baak1
  • Bogdan I. Florea8
  • Giel Hendriks9
  • Luciano De Petrocellis5
  • Herman S. Overkleeft8
  • Thomas Hankemeier4
  • Chris I. De Zeeuw7,10
  • Vincenzo Di Marzo5
  • Mauro Maccarrone11,12
  • Benjamin F. Cravatt2
  • Steven A. Kushner3,
  • Mario van der Stelt

  • A recent phase 1 trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 led to the death of one volunteer and produced mild-to-severe neurological symptoms in four others. Although the cause of the clinical neurotoxicity is unknown, it has been postulated, given the clinical safety profile of other tested FAAH inhibitors, that off-target activities of BIA 10-2474 may have played a role. Here we use activity-based proteomic methods to determine the protein interaction landscape of BIA 10-2474 in human cells and tissues. This analysis revealed that the drug inhibits several lipases that are not targeted by PF04457845, a highly selective and clinically tested FAAH inhibitor. BIA 10-2474, but not PF04457845, produced substantial alterations in lipid networks in human cortical neurons, suggesting that promiscuous lipase inhibitors have the potential to cause metabolic dysregulation in the nervous system.

    Covalent drug discovery using sulfur(VI) fluoride exchange warheads

    Huang Huang, Lyn H. Jones Expert Opinion on Drug Discovery , 2023 Covalent drug discovery has ...